Tumor-infiltrating T cells in Bcl9-shRNA compared to NT-shRNA bearing tumors exhibited pathways enriched for TLR, FOXP3, and IL-2 (Supplementary Fig. 8b, d). This evidence concerns the gene BCL9 and neoplasm.